Center for Bioethics Papers

Document Type

Journal Article

Date of this Version

February 2002

Comments

Postprint version. Published in Nature, Volume 415, February 2002, pages 577-599.
Publisher URL: http://dx.doi.org/10.1038/415577a

Abstract

Questions about the effects of patents and licensing are becoming critical in the United States, Europe and other developed countries as more genes are discovered and patented, and as genetic testing becomes an integral part of standard medical care. The award of patents for the diagnostic test for haemochromatosis, a progressive iron-overload disease, joins an ever-growing list of such tests that have been, or will very soon be, patented. We have found that US laboratories have refrained from offering clinical testing services for haemochromatosis because of the patents. A lot of clinical study is needed to validate and extend the early discovery of a disease gene such as that for haemochromatosis, so our results give us reason to fear that limiting clinical testing will inhibit further discovery as well as the understanding that emerges naturally from broad medical adoption.

Share

COinS
 

Date Posted: 21 May 2007

This document has been peer reviewed.